Wilson Sonsini Goodrich & Rosati advised Doron Therapeutics on the transaction. Doron Therapeutics, a clinical-stage biotech company focusing on degenerative musculoskeletal conditions, announced it has raised...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised IonQ on the transaction. IonQ (NYSE: IONQ), a leader in quantum computing, announced that it has reached a definitive agreement...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Pure Lithium on the transaction. Pure Lithium Corporation, a disruptive Boston-based vertically integrated lithium metal battery technology company, announced the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Pure Lithium on the transaction. Pure Lithium announced it secured $15 million in a Series A financing led by Oxy Low...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Tenaya Therapeutics on the transaction, and Davis Polk & Wardwell advised the underwriters. Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Motif Neurotech on the transaction. Neurotechnology company, Motif Neurotech announced it raised $18.75 million in oversubscribed Series A financing round. The...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Nature’s Toolbox on the transaction. Nature’s Toolbox (NTx) announced the close of a $47.5 million Series B funding round led by...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aqtual on the transaction. Aqtual announced it has completed a $16 million Series A round of financing co-led by Genoa Ventures,...
You must be a Standard 1 Year member to access this content.
